Abdelhakim Ahmed-Belkacem

9PUBLICATIONS
42CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsHaematologyMolecular targetsInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 17, 2026
Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses.

|Apr 28, 2023
Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity.

Jens Van Bael, Aline Vandenbulcke, Abdelhakim Ahmed-Belkacem

|Dec 06, 2022
Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry.

Margot Morin-Dewaele, Sophie Bartier, François Berry

|Sep 23, 2022
Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.

Abdelhakim Ahmed-Belkacem, Rabah Redjoul, Rozenn Brillet

|Feb 18, 2022
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.

Jean-Eudes Fahrner, Imran Lahmar, Anne-Gaëlle Goubet

|Jul 07, 2021
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis.

Anne-Gaëlle Goubet, Agathe Dubuisson, Arthur Geraud

Pageof 2

Frequent Collaborators

5 joint publications

Slim Fourati

4 joint publications

Jean-Michel Pawlotsky

2 joint publications

Anne-Gaëlle Goubet

2 joint publications

Agathe Dubuisson